Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study
Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study
复制标题
DOI：
10.1016/s0090-4295(00)01116-x
复制
发表时间：
2001-05-01
期刊：
影响因子：
2.1
通讯作者：
McKinlay, JB
中科院分区：
文献类型：
--
作者：
Mohr, BA;Feldman, HA;McKinlay, JB
目标。在基线年龄为40-70岁的男性样本中，确定诊断前血清激素是否可以预测前列腺癌风险。17种血清激素，包括雄激素、雌激素、肾上腺和脑下垂体激素，在基线(1987-1989)进行了测定，并利用马萨诸塞州男性老龄化研究的数据预测前列腺癌的发生(1995-1997)。在1576名男性中，有70名(4%)在基线和随访期(约8年)之间被诊断为前列腺癌。除雄烷二醇葡萄糖醛酸(AAG)与前列腺癌呈非线性负相关关系外，其他激素均与前列腺癌风险无关(P
Objectives. To determine whether prediagnostic serum hormones are predictive of prostate cancer risk in a sample of men 40 to 70 years old at baseline.Methods. Seventeen serum hormones, including androgens, estrogens, and adrenal and pituitary hormones, were measured at baseline (1987 to 1989) and used to predict incident prostate cancer by follow-up (1995 to 1997) using data from the Massachusetts Male Aging Study, a prospective, population-based random sample.Results. Seventy men (4%) of 1576 were diagnosed with prostate cancer between the baseline and follow-up periods (approximately 8 years). None of the hormones were associated with prostate cancer risk except for androstanediol glucuronide (AAG), which exhibited a nonlinear, inverse relationship with prostate cancer (P